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It has been suggested that ketamine cause injury during developing brain. Minocycline
(MC) could prevent neuronal cell death through the activation of cell survival signals
and the inhibition of apoptotic signals in models of neurodegenerative diseases. Here
we investigated the protective effect of MC against ketamine-induced injury in neural
stem cells (NSCs) from neonatal rat. Ketamine (100 µM/L) significantly inhibited NSC
proliferation, promoted their differentiation into astrocytes and suppressed neuronal
differentiation of NSCs. Moreover, the apoptotic level was increased following ketamine
exposure. MC pretreatment greatly enhanced cell viability, decreased caspase-3-
like activity, even reversed the differentiation changes caused by ketamine. To
elucidate a possible mechanism of MC’ neuroprotective effect, we investigated the
phosphatidylinositol 3-kinase (PI3K) pathway using LY294002, a specific PI3K inhibitor.
Immunoblotting revealed that MC enhanced the phosphorylation/activation of Akt and
phosphorylation/inactivation of glycogen synthase kinase-3beta (Gsk-3β). Our results
suggest that PI3K/Akt and Gsk-3β pathway are involved in the neuroprotective effect
of MC.
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INTRODUCTION
Ketamine, a noncompetitive blocker of N-methyl-D-aspartate (NMDA) receptor, is usually used
in children as anesthetics. Numerous studies have indicated that ketamine induce both neuron and
neural stem cell (NSC) injury in the developing brains in recent years, which calls for caution with
its use in neonatal and pediatric anesthesia (Ikonomidou et al., 1999; Hayashi et al., 2002; Young
et al., 2005; Slikker et al., 2007; Yan et al., 2014). Thus, development of adjunctive neuroprotective
measures that prevent or ameliorate neurotoxicity of ketamine is highly warranted.
As a second generation tetracycline, minocycline (MC) showed neuroprotective effects after both
focal and global cerebral ischemia (Yrjänheikki et al., 1998, 1999). It has also been reported that
the disease progression of amyotrophic lateral sclerosis and Huntington disease would be delayed
with MC treatment in mouse (Chen et al., 2000; Wang C. X. et al., 2003; Wang X. et al., 2003). MC
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also protects neurons against excitotoxic damage and nigral cell
loss (Du et al., 2001; He et al., 2001; Tikka and Koistinaho,
2001; Tikka et al., 2001; Wu et al., 2002). And evidences
indicated that, independently of its antimicrobial effect, MC
has anti-neuroinflammatory properties via inhibiting microglia
activation in the models of TBI-induced focal injury (Bye et al.,
2007; Homsi et al., 2010) and matter damage after excitotoxic
striatal injury (Guimarães et al., 2010). Some other mechanisms
have also been suggested to explain the neuroprotective
properties of MC, such as inhibition of caspase-1, caspase-3
(Chen et al., 2000), inducible nitric oxide synthase (iNOS)
expression (Amin et al., 1996; Lin et al., 2001), the mitochondrial
permeability transition pore (Du et al., 2001), mitochondrial
swelling (He et al., 2001), cytochrome c release (Zhu et al.,
2002) and inhibition of p38 MAP kinase (Lin et al., 2001).
However, whether MC protects NSCs from ketamine-induced
injury remains to be elucidated.
Akt is downstream target of phosphatidylinositol 3-kinase
(PI3K). The PI3K/Akt cascade has been reported to inhibit
apoptosis (Chalecka-Franaszek and Chuang, 1999) and promote
cell survival through insulin and growth factors (Franke et al.,
1995; Du et al., 1997). After phosphoinositide-dependent protein
kinase (PDK) phosphorylating Akt-1, glycogen synthase kinase
(Gsk) 3β, a serine/threonine kinase, is inhibited (Grimes and
Jope, 2001; Hur and Zhou, 2010). Studies have demonstrated
that Gsk-3β play an important role in fundamental functions
of cell, such as cell cycle, cytoskeletal integrity, apoptosis,
transcription factors expression and formation of neurofibrillary
tangles (Cross et al., 1995; Hetman et al., 2000; Grimes and Jope,
2001; Kandimalla et al., 2016). For example, Gsk-3β regulates
neurogenesis, neuronal polarization and axon growth in the
developing brain (Hur and Zhou, 2010). These findings implied
that PI3K kinase/Akt signaling pathway is related to the survival
of NSCs.
Given that MC improved the neurological outcome of
cerebral ischemia and some other neurodegenerative diseases,
we hypothesized that MC protects NSCs from ketamine-
induced impairment. Further, we analyzed the intracellular
signal transduction cascades involved in our study which showed
that the Akt/Gsk-3β pathway is related to MC protection against
the damage caused by ketamine.
MATERIALS AND METHODS
Cell Culture
New-born Sprague-Dawley rats were obtained from Laboratory
Animal Centre of Xi’an Jiaotong University School of Medicine.
This experiment was in accordance with the recommendations
of the National Institutes of Health Guide for the Care and
Use of Laboratory Animals (NIH Publications No. 80-23)
and the protocols were authorized by Committee on Animal
Care of Xi’an Jiaotong University. The animal procedures
were designed to minimize the number of animals required,
and appropriate steps were taken to avoid unjustified animal
procedures. This study was not involved in any vulnerable
populations, for example minors, persons with disabilities or
endangered animal species. Rat primary NSC cultures were
prepared from the dissected cortex of Sprague-Dawley rats
in 18–19 days of gestation under sterile condition. Briefly,
the forebrain portion dissected and placed in ice-cold Hank’s
solution (without Mg2+ and Ca2+, Gibco, Carlsbad, CA, USA).
The cells were then dissociated by mechanical agitation through
a fire-polished Pasteur pipette. After centrifugation, the isolated
cells were resuspended in free-serum DMEM/F12 medium
(Gibco, Carlsbad, CA, USA) which was supplemented with
2% B27 (Gibco, Carlsbad, CA, USA), 20 ng/ml EGF (Gibco,
Carlsbad, CA, USA), 20 ng/ml bFGF (Gibco, Carlsbad, CA,
USA) and 100 U/ml penicillin and phytomycin. A half of culture
mediumwas replaced every 3 days. According to the neurosphere
method developed by Reynolds and Weiss (Reynolds and
Weiss, 1992), cells were incubated for 7 days to form enough
neurospheres. Then the cells were passaged at a density of
2 × 105 cells/ml followed by collection and dissociation. The
medium was changed every 3 days. After the second passage,
nestin-positive cells were enriched in neurospheres with minimal
presence of β-tubulin III or glial fibrillary acidic protein (GFAP)-
positive cells, which indicated the characteristic of the NSC
preparation.
Measurement of Cell Viability
After passage, 5 × 103 cells were seeded each well in 96-well
plates, then Cell Counting Kit-8 (CCK-8, Beyotime Institute
of Biotechnology, shanghai, China) was used to detect the cell
viability by adding 10 µl CCK-8 solution per well. At the
wavelength of 450 nm on amicroplate reader, the Optical density
(OD) value was measured 4 h later, and the value was corrected
by subtracting the absorbance of control wells that did not
contain cells. Data were collected from at least three independent
experiments.
5-Bromo-2′-deoxyuridine (BrdU)
Incorporation Assay
After passage, the cells were seeded on cover slips which
processed by 100 µg/mL poly-L-lysine and incubated with
the proliferation marker 5-Bromo-2′-deoxyuridine (BrdU; 10
µmol/L, Sigma-Aldrich Inc. St. Louis, MO, USA) for 4 h.
Before staining with 4′,6-diamidino-2-phenylindole (DAPI) and
BrdU antibody (Sigma-Aldrich Inc. St. Louis, MO, USA) cells
were fixed by 4% paraformaldehyde. Immunoreactive cells were
visualized by fluorescence microscopy (Olympus, BX51, Japan)
and a total of 5–7 randomly selected fields were captured. The
minimal number of cells for counting was 200 in each condition,
and data were collected from at least three independent
experiments.
Measurement of Cell Differentiation
After passage, the cells were seeded on cover slips which
processed by 100 µg/mL poly-L-lysine and incubated with
differentiating medium which contains 100 × N2 supplement,
100 × B27 supplement and 1% fetal bovine serum (FBS, Gibco,
Carlsbad, CA, USA) in DMEM/F12 (without b-FGF). At the
end of 7 day cultures, cells were harvested for differentiation
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analysis. A total of 5–7 randomly selected images were taken
in each well, and the number of cells expressing β-tubulin III,
GFAP tested by β-tubulin III antibody (Sigma-Aldrich Inc. St.
Louis, MO, USA) and GFAP antibody (Sigma-Aldrich Inc. St.
Louis, MO, USA) were counted (at least 200 cells each test
case), and data were collected from at least three independent
experiments.
Western Blot Analysis
Following exposure to ketamine and/or MC, cells were washed
with ice-cold D-hanks’ solution three times and then lysed with
lysis buffer containing protease and phosphatase inhibitors. The
cell lysates were placed on ice for 15 min and centrifuged at
14,000 rpm for 15 min at 4◦C. Protein concentrations in the
resulting lysates were determined with a BCA protein assay
kit, bovine serum albumin (BSA) was used as a standard.
Equal amount of the resulting cell lysate was resolved by
sodium dodecyl sulfate-polyacrylamide gel and the separated
proteins were transferred to polyvinylidene fluoride membranes.
The membranes were incubated with blocking buffer for 1 h
at room temperature and then incubated for 16 h at 4◦C
with primary antibodies (Cell Signal Technology Inc, Beverly,
MA, USA) raised to β-tubulin III, GFAP, caspase-3, phospho-
Akt, Akt, phosphor-Gsk-3β, Gsk-3β and β-actin. The signals
were detected using goat anti-rabbit or anti-mouse horseradish
secondary antibody followed by enhanced chemiluminescence
(ECL). After exposing to X-ray films, blots from at least three
independent tests were quantified as OD values according to
their controls.
Statistical Analysis
For statistical analysis, differences between animals were
evaluated through one-way analysis of variance (ANOVA) and
post hocDuncon’s test. Data which expressed as the mean± SEM
were analyzed by SPSS for Windows version 18.0 and Prism 5.
Statistical significance was set at P < 0.05.
RESULTS
Culture and Identification of NSCs
To begin this experiment, neocortical tissues of E18-19 Sprague-
Dawley rats were dissected for NSC culture. The suspended
growth of neurospheres was notably observed 3 days after
seeding. As we can see cells expressing Nestin (Figure 1A),
a marker for NSCs, reached to 50%–60% of total cells in a
neurosphere, which was consistent with the previous study.
In the adherent culture system, NSCs also expressed Nestin
(Figure 1A) after seeded on PLL. It is known that neurons,
astrocytes and oligodendrocytes could be generated from NSCs
by differentiation. To determine this feature of NSCs, cells
were immunostained against β-tubulinIII, a specific maker for
neuron (green) and GFAP, a specific maker for astrocytes (red;
Figure 1B) after 7 days of differentiation. Overall, most of
cells in this experiment were NSCs which characterized by the
proliferation potential and the capability to differentiate into
multiple cell types.
FIGURE 1 | Culture and identification of neural stem cells (NSCs).
(A) Cell morphology and nestin expressions. (a–c) Immunostaining of the
Nestin (green) in neurosphere before seeded on substrates.
(d–f) Immunostaining of the Nestin (green) in neurosphere after seeded on
PLL. Cell nuclei was stained with 4′,6-diamidino-2-phenylindole (DAPI; blue).
(B) Representative immunofluorescence images of the cultures at day 7, as
one characteristic of NSCs, the cells differentiated into neurons and
astrocytes. (a) Immunostaining of the β-tubulin III (green) of the cultures.
(b) Immunostaining of the glial fibrillary acidic protein (GFAP; red) of the
cultures. (c) Cell nuclei was stained with DAPI (blue). (d) Merge picture of
(a–c). Scale bar = 25 µm.
Minocycline Elicited a
Concentration-Dependent Viability
Increase in NSCs Exposed to Ketamine
In this study, the injury of ketamine in cortical NSCs were
first tested by CCK-8 (Figure 2A). Compared with vehicle
controls, exposed to ketamine (from 50 µM/L to 200 µM/L,
Sigma-Aldrich Inc. St. Louis, MO, USA) for 24 h significantly
decreased cell viability, and 100 µM/L ketamine resulted in the
minimal survival of 33.3% of NSCs. Pre-treatment of NSCs with
MC (10, 20, 50, 100, 200 µM/L, Sigma-Aldrich Inc. St. Louis,
MO, USA) for 30 min before ketamine exposure, the survival
rate of NSCs was 39.5 ± 8%, 50.6 ± 6%, 92.8 ± 5% and
87.7 ± 8%, respectively (Figure 2B), indicating dose-dependent
neuroprotective effect of MC on NSCs. It is worth to notice that
there was no significant difference in the cell number between
groups with different doses of MC. The maximal rescue occurred
at a concentration of 50 µM/L MC. Therefore, NSCs were
co-treated with 100 µM/L ketamine and 50 µM/L MC for the
further study.
Minocycline Elicited a Time-Dependent
Viability Increase in NSCs Exposed to
Ketamine and Phosphatidylinositol
3-Kinases (PI3K) Pathway was Involved
To evaluate the neuroprotection of MC persistently, the cell
viability at 0 h, 6 h, 12 h, 24 h and 48 h were tested and
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FIGURE 2 | Inhibition by minocycline (MC) on ketamine-induced injury. (A) Ketamine induced a dose-dependent damage. NSCs were exposed to
10–200 µM/L ketamine for 24 h, then cell viability was measured by Cell Counting Kit-8 (CCK-8) assay. (B) MC prevented ketamine-induced injury
dose-dependently. NSCs were exposed to different concentrations of 10–100 µM/L MC for 30 min before the addition of 100 µM/L ketamine. Cell viability was
measured by CCK-8 assay at 24 h after ketamine addition. Data, as expressed percentage of control (Con), are the mean ± SEM of four separate experiments
(n = 6 for each group). ∗p < 0.05 and ∗∗p < 0.01 vs. control; NP < 0.05 and NNP < 0.01 vs. ketamine.
we found that 100 µM/L ketamine caused a time-dependent
viability decrease of NSCs but 50 µM/L MC exhibited protective
effect lasting from 6 h to 48 h after ketamine exposure, besides
the viability of NSCs in the control group did not change at
the above time points (Figure 3A). To establish the temporal
profile of MC’s effect, NSCs were exposed to 50 µM/L MC
for 0.5 h, 1 h, 2 h before ketamine was added. In order to
examine the acute effect of MC, it was also added to NSC
FIGURE 3 | MC elicits a time-dependent protective effect against ketamine-induced injury, but this protection was inhibited by specific
phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Cell survival was measured at 24 h after ketamine exposure by CCK-8 assay. (A) Viability comparison
of normal NSCs with those exposed to 100 µM/L ketamine alone or exposed to 100 µM/L ketamine plus 50 µM/L MC for 6–48 h. (B) NSCs were exposed to
50 µM/L MC at −2 h, −1 h or −0.5h before 100 µM/L ketamine and 0 h, 0.5 h, 1 h or 2 h after ketamine. (C) Pre-incubation with LY294002 (20 µM/L) resulted in
the elimination of the protective effect induced by 50 µM/L MC. Data are the mean ± SEM of three independent experiments (n = 6 for each group). ∗p < 0.05 and
∗∗p < 0.01 vs. control; NP < 0.05 and NNP < 0.01 vs. ketamine. 4P < 0.05 vs. ketamine plus MC.
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culture at 0 h, 0.5 h, 1 h, 2 h after ketamine exposure. Cell
viability was examined 24 h after ketamine insult. The result
indicated that MC induced a time-dependent viability increase in
NSCs, but considering the experimental operability and clinical
practical, NSCs were pretreated withMC 30min before ketamine
exposure for the further study. It is worth noting that even
when added at the same time with ketamine, NSC viability
increased gently but significantly by MC treatment (Figure 3B).
However, if adding at 30 min after ketamine exposure, MC
did not display any protective effect against NSCs exposed to
ketamine.
To investigate whether the protective effect of MC had
connection with PI3K signaling pathway, LY294002 was used
120 min before ketamine exposure. The survival rate of NSCs
was 92.7 ± 7% after preconditioned with MC. However,
with LY294002 (20 µM/L), NSC viability was approximately
57.2 ± 6%, indicating that MC lost its protection in the presence
of LY294002 (Figure 3C).
Minocycline Changed the Effect of
Ketamine on NSC Proliferation
NSC proliferation was determined by BrdU incorporation
staining, as an analog of thymidine, BrdU can be incorporated
into the newly synthesized DNA of replicating cells during
the S phase of the cell cycle. After ketamine exposure
(100 µM/L; 24 h), BrdU positive cells were remarkably
decreased compared to the control. On the contrary,
50 µM/L MC barely restored the proliferation rate to
normal level. However, in the group pretreated with
LY294002 (20 µM/L), the proliferation rate of NSCs was
only 62.2 ± 7% of control group, indicating that PI3K pathway
maybe involved in the protective effect induced by MC
(Figures 4A,B).
Minocycline Alleviated the Effect of
Ketamine on NSC Differentiation
Both immunostaining (Figures 5A,B) and western blot
(Figures 5C,D) demonstrated that the cultured cells can
differentiate into different type of cells, including astrocytes
and neurons. Furthermore, it was shown that after ketamine
treatment, the percentage of neuron was decreased, and
MC increased the differentiation of NSCs towards neuron
(Figures 5B,D). On the contrary, MC preconditioning strongly
inhibited NSC differentiation towards astrocytes which was
increased by ketamine exposure (Figures 5B,D). The effect
of MC on NSC differentiation was reversed by LY294002,
indicating that PI3K pathway maybe involved in the protective
effect induced by MC (Figure 5).
Minocycline Alleviated Ketamine-Induced
Apoptosis by Activating the PI3K Signaling
Pathway
Caspase-3 is often associated with apoptosis. In this study,
experiments were carried out by western blot analysis
to detect the difference of caspase-3 expression between
three groups. Ketamine exposure produced an increase in
the expression of caspase-3 compared with the control.
Pretreatment with 50 µM/L MC decreased the caspase-3
expression after ketamine exposure. However, co-treatment
with 20 µM/L LY294002, reversed the protective effect of MC
(Figures 6A,B).
Minocycline Reversed the Inhibitory Effect
of Ketamine to PI3K/Akt Pathway
As number of previous researches indicated that the
neuroprotection of MC was associated with the phosphorylation
FIGURE 4 | Effect of MC on NSC proliferation by 5-Bromo-2′-deoxyuridine (BrdU) incorporation assay. (A) Representative immunofluorescence images of
BrdU positive cells in the four groups. Cells were stained for BrdU (red) and DAPI for the nucleus (blue). Scale bar = 50 µm. (B) Quantitative analysis of BrdU staining
in the experimental groups. Dates are the mean ± SEM of three independent experiments (n = 6 for each group); ∗∗P < 0.01 vs. control; NNP < 0.01 vs. ketamine;
∆P < 0.05 vs. ketamine plus MC.
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FIGURE 5 | NSC differentiation on day 7 of culture. (A) Representative immunofluorescence images of NSCs differentiated neurons and astrocytes in the four
groups. Cells were stained for β-tubulin III (green), GFAP (red) and DAPI for the nucleus (blue). Scale bar = 25 µm. (B) Quantitative analysis of β-tubulin III and GFAP
staining in the experimental groups. Dates are the mean ± SEM of three independent experiments (n = 6 for each group); ∗∗P < 0.01 vs. control; NNP < 0.01 vs.
ketamine; ∆∆P < 0.01 vs. ketamine plus MC. (C) Representative images of β-tubulin III and GFAP expression by western blot in the four groups. (D) Quantitative
analysis of β-tubulin III and GFAP expressions normalized to β-actin. Data were expressed as the ratio to optical density (OD) values of the corresponding controls
and showed as the mean ± SEM of three independent experiments (n = 6 for each group); ∗∗P < 0.01 vs. control; NNP < 0.01 vs. ketamine; ∆∆P < 0.01 vs.
ketamine plus MC.
of Akt and considering that LY294002 almost completely
abolished the protection of MC to NSC injury induced by
ketamine, we examined the expression level of Akt/PKB, a
downstream effector of PI3K which had been demonstrated
to promote cell survival. In this study NSCs exposed to
ketamine for 6 h lead to decreased p-Akt levels significantly,
which last for 48 h in a time-dependent manner. Pretreatment
with MC reversed the effect of ketamine in p-Akt levels
in NSCs. Moreover, 20 µM/L LY294002 weakened the
protective effect of MC for at least 48 h. There was no
significant difference in total amount of Akt in our observation
(Figures 7A,B).
It is known that decreased p-Akt induces lower
phosphorylation of Gsk-3β to p-Gsk-3β. Therefore, the
level of phosphorylated Gsk-3β was analyzed at 0 h, 6 h,
12 h, 24 h and 48 h followed by ketamine treatment. In
this study NSCs exposed to ketamine for 6 h leads to
decreased p-Gsk-3β level significantly, which lasts for 48 h
in a time-dependent manner. Pretreament with MC reversed
the effect of ketamine on p-Gsk-3β levels in NSCs. Moreover,
20 µM/L LY294002 weakened the protective effect of MC for
at least 48 h. No alteration in the total amount of Gsk-3β was
observed (Figures 7C,D). Our results indicated that Gsk-3β, as
the crucial substrate of Akt, was involved in the protective effect
of MC against ketamine insult.
DISCUSSION
Ketamine has been reported to induce injury in the developing
brain (Liu et al., 2011), whereas how ketamine affect the
neurogenesis in this period is not very clear. Given the
importance of NSCs in neurogenesis, we investigated the effect
of ketamine on proliferation and differentiation of NSCs from
embryonic day 18–19 rat in vitro. We also observed whether
MC can prevent ketamine-induced injury and the possible
intracellular signaling pathway. The key findings are that MC
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FIGURE 6 | Western blot analysis of the caspase-3 expression.
(A) Representative images of the caspase-3 and β-actin expression by
western blot in the four groups. (B) Quantitative analysis of caspase-3
expressions normalized to β-actin. Data were expressed as the ratio to OD
values of the corresponding controls and showed as the mean ± SEM of
three independent experiments (n = 6 for each group); ∗∗P < 0.01 vs. control;
NNP < 0.01 vs. ketamine; ∆∆P < 0.01 vs. ketamine plus MC.
attenuated ketamine-induced NSC injury by inhibiting Gsk-
3β activity and maintaining the PI3K/Akt pathway activation
in vitro.
NSCs are self-renewal and multipotential cells that can
generate neurons and glia. It plays an important role in
neurogenesis and gliogenesis in the development of the central
nervous system. In humans, the brain growth spurt (BGS)
proceeds from the third trimester until approximately 2 years
after birth. In rats, this period corresponds to the first
21 postnatal days (PNDs). We investigated the effect of ketamine
on NSCs from embryonic day 18–19 rats, which is equivalent to
human BGS.
The potential toxic effect of different concentration of
ketamine on cultured NSCs were examined first, it was observed
that ketamine (10 and 20 µM/L) failed to alter the NSC
viability. Ketamine at the concentration of 50, 100 and 200 µM/L
significantly inhibited the NSC viability through PI3K/Akt/Gsk-
3β signaling pathway in vitro. Studies have shown that plasma
concentration of ketamine in different patients who were given
2.0–2.2 mg/kg of it by intravenous injection would reach a peak
at 108.4 µM vs. a valley at 37.8 µM 1 min later (Domino
et al., 1982). So further investigation definitely need to be done
to explore the effect of ketamine on the brain development at
clinical relevant doses.
Neurogenesis is characterized by three stages: (1) cell
proliferation for generation of new cells; (2) cell migration
which is the movement of newly generated cells to their
final destination; and (3) cell differentiation for taking on
the appearance and function of a neuron, astrocyte and
oligodendrocyte (Zhao et al., 2008). By using BrdU label method,
it is shown that the proliferation of NSCs was significantly
decreased after ketamine exposure, which is consistent with
Dong’s study (Dong et al., 2012). However, there is a discrepancy
between our findings and Bai et al. (2013) who revealed that the
proliferation of NSCs from human embryonic stem cells (hESCs)
was increased followed by 100 µM/L ketamine treatment for 6 h
in vitro. NSC source and experiment protocol might contribute
to the contradiction between our findings and Bai et al.’s
(2013).
FIGURE 7 | MC reverses the inhibitory effect of ketamine by PI3K/Akt
pathway. (A,B) MC time-dependently prevented ketamine-evoked decrease
of p-Akt. (A) Representative images of p-Akt, Akt and β-actin expression by
western blot in the four groups. (B) Quantitative analysis of p-Akt, Akt and
β-actin expressions normalized to β-actin. (C,D) MC time-dependently
prevented ketamine-evoked decrease of p-Gsk-3β. (C) Representative images
of p-Gsk-3β, glycogen synthase kinase-3beta (Gsk-3β) and β-actin expression
by western blot in the four groups. (D) Quantitative analysis of p-Gsk-3β,
Gsk-3β and β-actin expressions normalized to β-actin. Data were expressed
as the ratio to OD values of the corresponding controls and showed as the
mean ± SEM of three independent experiments (n = 6 for each group);
∗∗P < 0.01 vs. control; NNP < 0.01 vs. ketamine; ∆∆P < 0.01 vs. ketamine
plus MC.
There are three major cell types from the differentiation of
NSCs as neurons, astrocytes, and oligodendrocytes (Wang et al.,
2013). It is known that accepting and producing information
are basic functions of neurons meanwhile the glia is important
for providing the microenvironments to support and nourish
the neurons. Hence regulating the NSC maintenance and
differentiation determines the growth and function of the
developing brain. A better understanding of NSC differentiation
is crucial for dissecting the underlying mechanisms associated
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with ketamine induced injury (Wang et al., 2013). In this
study immunostaining was performed with a neuron-specific
marker—β-tubulin III antibody and an astrocyte (glia)-specific
marker—GFAP antibody which showed that the differentiation
of astrocytes was enhanced while the differentiation of neurons
was decreased by ketamine exposure, but 50 µM/L MC barely
reversed this differentiation changes which may cause potential
functional injury. What surprises us is that the effect of
MC on differentiation of NSCs was attenuated by LY294002,
however, the underlying mechanism need to be exploited in the
future.
PI3K is an agonist-activated lipid signaling enzyme that
initiate signaling cascades which has emerged as a master
regulator of cell through activation of the Akt (Toker, 2000). For
instance, low level of NMDA, which has a recognized role in
a variety of neuronal physiological and pathological processes,
can activate Akt to promote neuronal survival (Sutton and
Chandler, 2002). As results from cell viability, immunostaining
and western blot strongly suggested that the PI3K signaling
pathway is involved in the protective effect of MC in this
experiment, we explored the PI3K pathway using LY294002,
an inhibitor of PI3K. In agreement with a previous report
which showed the activity of Gsk-3β, a substrate of Akt,
is suppressed by MC in erythroid progenitors (Somervaille
et al., 2001). Our data demonstrated that MC was able to
increase the level of Gsk-3β in parallel with the activation of
Akt. It was also showed that LY294002 blocked MC-induced
phosphorylation of Akt and Gsk-3β. Overall, these results
indicating the injury induced by ketamine and the beneficial
effect of MC was mediated by PI3K/Akt-dependent Gsk-3β
phosphorylation.
In this study, theMC concentrations used ranged from 10µM
to 100 µM in NSCs. This was based on the fact that the
neuroprotective dose of MC are approximately at 50–100 µM/L
in vitro studies (Lin et al., 2001; Wang X. et al., 2003), or
probably 200–400 µM/kg in vivo tests (Yrjänheikki et al., 1998;
Fagan et al., 2004) which is quite different from its antibacterial
concentrations (about 4.3–11.0 Mm/L; Zhu et al., 2002; Fagan
et al., 2004).
CONCLUSION
Our study demonstrated that MC exerted protective effect
against the injury induced by ketamine in NSCs and
PI3K/Akt/Gsk-3β signaling pathway was involved. The results
are helpful in designing clinical studies for treatment of ketamine
injury in youngsters. Finally further experiments should be
conducted to clarify the safety and underlying mechanism of MC
to behave as a neuroprotective drug.
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